Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, takin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-07-01
|
| Series: | Asian Journal of Urology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221438821730053X |
| _version_ | 1818472181463515136 |
|---|---|
| author | Cheuk Fan Shum Weida Lau Chang Peng Colin Teo |
| author_facet | Cheuk Fan Shum Weida Lau Chang Peng Colin Teo |
| author_sort | Cheuk Fan Shum |
| collection | DOAJ |
| description | Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, taking into consideration various factors like efficacy, dosing regime, adverse effects, cost, patient's socioeconomic background, expectations, drug availability and his own clinical experience. The use of combination therapy added further to the complexity in clinical judgment when prescribing. We highlight some of the key points in prescribing α1 antagonists, 5ARi and their combination, based on our viewpoints and experience as urologists in an Asian clinical setting. Keywords: 5α Reductase inhibitors, Adrenergic α1 receptor antagonists, Drug therapy, Combination, Prostatic hyperplasia |
| first_indexed | 2024-04-14T04:02:05Z |
| format | Article |
| id | doaj.art-fbbf9e4d2ca4495e98d8f639bde31c1c |
| institution | Directory Open Access Journal |
| issn | 2214-3882 |
| language | English |
| last_indexed | 2024-04-14T04:02:05Z |
| publishDate | 2017-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj.art-fbbf9e4d2ca4495e98d8f639bde31c1c2022-12-22T02:13:30ZengElsevierAsian Journal of Urology2214-38822017-07-0143185190Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combinationCheuk Fan Shum0Weida Lau1Chang Peng Colin Teo2Corresponding author.; Department of Urology, Khoo Teck Puat Hospital, SingaporeDepartment of Urology, Khoo Teck Puat Hospital, SingaporeDepartment of Urology, Khoo Teck Puat Hospital, SingaporeMedical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, taking into consideration various factors like efficacy, dosing regime, adverse effects, cost, patient's socioeconomic background, expectations, drug availability and his own clinical experience. The use of combination therapy added further to the complexity in clinical judgment when prescribing. We highlight some of the key points in prescribing α1 antagonists, 5ARi and their combination, based on our viewpoints and experience as urologists in an Asian clinical setting. Keywords: 5α Reductase inhibitors, Adrenergic α1 receptor antagonists, Drug therapy, Combination, Prostatic hyperplasiahttp://www.sciencedirect.com/science/article/pii/S221438821730053X |
| spellingShingle | Cheuk Fan Shum Weida Lau Chang Peng Colin Teo Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination Asian Journal of Urology |
| title | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination |
| title_full | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination |
| title_fullStr | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination |
| title_full_unstemmed | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination |
| title_short | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination |
| title_sort | medical therapy for clinical benign prostatic hyperplasia α1 antagonists 5α reductase inhibitors and their combination |
| url | http://www.sciencedirect.com/science/article/pii/S221438821730053X |
| work_keys_str_mv | AT cheukfanshum medicaltherapyforclinicalbenignprostatichyperplasiaa1antagonists5areductaseinhibitorsandtheircombination AT weidalau medicaltherapyforclinicalbenignprostatichyperplasiaa1antagonists5areductaseinhibitorsandtheircombination AT changpengcolinteo medicaltherapyforclinicalbenignprostatichyperplasiaa1antagonists5areductaseinhibitorsandtheircombination |